Meeting
2024 ASCO Annual Meeting
ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.
Authors
Oliver Sartor
Mayo Clinic, Rochester, MN
Oliver Sartor , Scott T. Tagawa , Nat Lenzo , David Cade , Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT04876651
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS5115)
DOI
10.1200/JCO.2024.42.16_suppl.TPS5115
Abstract #
TPS5115
Poster Bd #
517a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Safety, tolerability, and dosimetry of 177Lu-TLX591 with best standard of care in patients with PSMA-expressing metastatic castration-resistant prostate cancer (ProstAct-SELECT).
First Author: Nat Lenzo
Poster
2023 ASCO Annual Meeting
Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa).
First Author: Daniel Sentana Lledo
Poster
2023 ASCO Annual Meeting
CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).
First Author: Jesse Meir Zaretsky
Poster
2023 ASCO Genitourinary Cancers Symposium
Increased utilization of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (PSMA-TRT) in African American (AA) patients at an academic medical center.
First Author: Joseph Earl Thomas